Please login to the form below
BI
This page shows the latest BI news and features for those working in and with pharma, biotech and healthcare.
BMS pays Zenas $50m upfront for regional rights to autoimmune disease antibody
Bristol Myers Squibb (BMS) and Zenas BioPharma have entered into a strategic license and collaboration agreement to develop and commercialise a novel, bi-functional antibody called obexelimab for autoimmune diseases. ... Obexelimab is an investigational
Latest news
-
Janssen’s Talvey granted FDA accelerated approval for difficult-to-treat blood cancer
Talvey, which is administered as a weekly or bi-weekly subcutaneous injection after an initial step-up phase, is a bispecific antibody that binds to CD3 on the surface of T
-
Janssen receives positive CHMP opinion for Talvey in multiple myeloma
Janssen, a Johnson &Johnson company, has announced that its bi-specific antibody, Talvey (talquetamab), has been recommended by the European Medicines Agency’s (EMA) human medicines committee for use in certain ... Despite recent advances, Janssen
-
Roche partners with Alnylam on hypertension therapy in deal worth up to $2.8bn
The Swiss pharma added that the therapy also has the potential to improve adherence and compliance to treatment due to its possible bi-annual subcutaneous dosing regime.
-
Biogen/Eisai’s Alzheimer’s disease drug shows promise as a subcutaneous formulation
Leqembi was granted traditional approval in the US earlier this month as a bi-weekly intravenous infusion. ... New results from an exposure/bioavailability and modelling study, presented at AAIC, show a SC dose of Leqembi administered once-weekly may
-
Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
Boehringer Ingelheim (BI) has reported positive results from its phase 2b trial of spesolimab, demonstrating that the anti-interleukin-36 receptor antibody can prevent flares in adolescent and adult patients with ... BI reports that there is a ‘high
More from news
Approximately 4 fully matching, plus 111 partially matching documents found.
Latest Intelligence
-
The role of digital health technology tools in supporting medical adherence
A true bi-directional conversation will reveal risks for non-adherence that can be addressed in prescriber-patient discussions.
-
CAR-T cell therapy in oncology
Simultaneously targeting multiple tumour antigens using bi-specific chimeric antigen technology. Summary.
-
Putting the ovation into innovation: trends from ESMO
toxicity, including innovative bispecific monoclonal antibodies and Bi-specific T-cell engagers.
-
The ‘Million Hour Challenge’
Since the initiative launched, AstraZeneca has seen two consecutive increases in the bi-annual employee engagement survey, with 69% of AstraZeneca employees agreeing that ‘Together, we are making progress in our
-
Is it time we stopped talking about adherence?
attractive and valuable bi-product.
More from intelligence
Approximately 0 fully matching, plus 26 partially matching documents found.
Latest from PMHub
-
Listening to heads AND hearts in healthcare
We talk a lot about using emotions in healthcare communications, but not as much about the business intelligence(BI) behind it. ... What we don’t talk about as much is the business intelligence (BI) behind it.
-
Origins Insights wins the “Best Patient-Centric Approach” award at the BHBIA BOBI Awards 2021
patient voice and the critical role of BI in ensuring this is heard.
-
Havas Lynx Group
AbbVie. ALK. Astellas. AstraZeneca. Bayer. Boehringer Ingelheim. BI. BMS. Celgene. Sanofi Genzyme.
-
CSL
CSL are a healthcare specialist business intelligence consultancy. We help companies utilise tools like Power BI &Tableau.
-
New Leaf Technology Solutions Ltd
market in areas such as Incentive Compensation, KAM, Coaching, Collaboration platforms and BI sol.
More from PMHub
Approximately 1 fully matching, plus 12 partially matching documents found.
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
